Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002630 · ClinicalTrials.gov registry record · Phase 2
High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse
A Phase 2 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00002630: Completed Phase 2 study, sponsored by Mayo Clinic.
NCT00002630 is a Phase 2 study that has completed, run by Mayo Clinic. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002630, a Phase 2 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining peripheral stem cell transplantation with chemotherapy and radiation therapy may allow the doctor to give higher doses of radiation and chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-dose melphalan plus total-body irradiation and peripheral stem cell transplantation in treating patients with multiple myeloma in first relapse.
Interventions
- DRUG cyclophosphamide
- DRUG melphalan
- PROCEDURE peripheral blood stem cell transplantation
- BIOLOGICAL filgrastim
- RADIATION low-LET cobalt-60 gamma ray therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 1993-06 |
| Est. Completion | 2001-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002630
The ClinicalTrials.gov registry entry for NCT00002630 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00002630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002630 about?
NCT00002630 is a clinical study titled "High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining peripheral stem cell transplantation with chemotherapy and radiation therapy may allow the doctor to give...
What is the current status of trial NCT00002630?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 1993-06. Estimated completion is 2001-05.
What interventions are being tested in trial NCT00002630?
The interventions under investigation include: cyclophosphamide (DRUG), melphalan (DRUG), peripheral blood stem cell transplantation (PROCEDURE), filgrastim (BIOLOGICAL), low-LET cobalt-60 gamma ray therapy (RADIATION).
Who is sponsoring clinical trial NCT00002630?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.